Estudo randomizado | Ecopipam para síndrome de Tourette

Ecopipam for Tourette Syndrome: A Randomized Trial – Pediatrics

Comentário: Ecopipam May Reduce Tics in Children With Tourette Syndrome – Psychiatric News Alert

Comentário no Twitter

Ecopipam, a selective D1-like receptor antagonist, is in development for children & adolescents with Tourette syndrome. Can ecopipam achieve a clinically meaningful reduction in tics without the disadvantages of D2-like receptor antagonists? https://t.co/GXxnPsP74C #Pediatrics pic.twitter.com/14fwu4npJi

— AAP Pediatrics (@aap_peds) January 11, 2023